This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
The four strategies were usual care with no prevention, prevention according to guidelines, screening by CT to determine risk, and prevention for all (low-dose statin therapy).
The prevention guidelines recommended lifestyle advice for all, statin therapy when a patient's baseline low-density lipoprotein (LDL) cholesterol was over 130mg per dL, and antihypertensive medication when their baseline systolic blood pressure exceeded 140mmHg.
CT screening determined the coronary calcium score. Patients at low risk received lifestyle advice and pharmacological treatment if their systolic blood pressure was above 140mmHg or their plasma LDL-cholesterol level was over 160mg per dL. Patients at intermediate risk received treatment according to the prevention guidelines. Patients at high risk received lifestyle advice, statin therapy, and antihypertensive medication, irrespective of their cholesterol and blood pressure levels (men also received low-dose aspirin).
Location/setting
USA/primary and secondary care.
Methods

Analytical approach:
The analysis was based on a Markov model, with a lifetime horizon. The authors stated that it was carried out from the perspective of society.
Effectiveness data:
The clinical data were from relevant studies. The patients' characteristics and the ability of CT screening to determine low, intermediate, and high risk came from a cohort study (the Rotterdam study) of 2,028 people who underwent CT to determine their coronary calcium score and were followed-up for a median of 9.2 years. The 10-year risk of CHD was calculated using either the conventional Framingham risk model or the CT calcium prediction model and this was the key input for the model. Other inputs were from published meta-analyses, official life tables, or expert opinion.
Results
In asymptomatic men, the lifetime costs were $7,551 with usual care, $10,276 with statin therapy, $12,184 with guideline prevention, and $12,228 with CT screening. The QALYs were 10.03 with usual care, 10.12 with statin therapy, 10.14 with guideline prevention, and 10.16 with CT screening. Women had higher costs and lower QALYs.
Compared with the next-best strategy, for men, guideline prevention was extendedly dominated, as it was less effective and less cost-effective than another option. The incremental cost per QALY gained was $30,278 with statin therapy, over usual care, and $48,800 with CT screening, over statin therapy.
In women, CT screening was extendedly dominated and the incremental cost per QALY gained was $23,910 with statin therapy, over usual care, and $51,400 with guideline prevention, over statin therapy.
At a WTP threshold of $50,000, the best strategy depended on the model assumptions.
In men, statin therapy was the best strategy if there was a slight lack of synergy between drugs, if treatment adherence dropped below 58%, if the effect of aspirin therapy on CHD was reduced, if the cost of a CT scan was over $200, or if the risk of radiation-induced cancer increased more than 10-fold. In women, statin therapy was the best strategy if there was a slight lack of synergy between drugs.
In men, CT screening was cost-effective in most simulations at a WTP threshold of $50,000 per QALY. In women, CT screening was cost-effective in less than 20% of simulations even at higher WTP thresholds.
